<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2022</Year>
        <Month>01</Month>
        <Day>02</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Flow Cytometric DNA Ploidy Analysis in Haemato-Lymphoid Neoplasms: An Analysis of 132 Cases</title>
    <FirstPage>34</FirstPage>
    <LastPage>46</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Nishit</FirstName>
        <LastName>Gupta</LastName>
        <affiliation locale="en_US">Department of Haematology, BLK Superspeciality Hospital, Delhi, India, 110005</affiliation>
      </Author>
      <Author>
        <FirstName>Aditi</FirstName>
        <LastName>Mittal</LastName>
        <affiliation locale="en_US">Department of Haematology, BLK Superspeciality Hospital, Delhi, India, 110005</affiliation>
      </Author>
      <Author>
        <FirstName>Tina</FirstName>
        <LastName>Dadu</LastName>
        <affiliation locale="en_US">Department of Haematology, BLK Superspeciality Hospital, Delhi, India, 110005</affiliation>
      </Author>
      <Author>
        <FirstName>Dharma</FirstName>
        <LastName>Choudhary</LastName>
        <affiliation locale="en_US">Department of Hemato-oncology and Bone marrow transplant, BLK Superspeciality Hospital, Delhi, India, 110005</affiliation>
      </Author>
      <Author>
        <FirstName>Anil</FirstName>
        <LastName>Handoo</LastName>
        <affiliation locale="en_US">Department of Haematology, BLK Superspeciality Hospital, Delhi, India, 110005</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2020</Year>
        <Month>05</Month>
        <Day>14</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2020</Year>
        <Month>12</Month>
        <Day>16</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: FxCycleTM Violet (FCV) based flow cytometric (FCM) DNA ploidy analysis is a rapid and simple tool that can substantiate in characterizing the biological behaviour across the spectrum of haematological malignancies and correlates with cytogenetic studies.
&#xD;

Materials and Methods: In this prospective study, we performed simultaneous immunophenotyping with FCV based on&#xA0; ploidy analysis in n=132 consecutive new samples, comprising n=110 samples of haemato-lymphoid neoplasms, including acute leukemias (n=67, 60.9%), CML with myeloid blast crisis (n=1, 0.9%), MDS with excess blasts (n=2, 1.8%), mature B cell/ T cell neoplasms (n=37, 33.7%), multiple myeloma (n=3, 2.7%) along with n=22 normal samples. The FCM DNA data was compared with corresponding conventional karyotyping results, wherever available.
&#xD;

Results: In FCM ploidy analysis (n=110), the overall DNA index (DI) ranged from 0.81 to 2.17 and S-Phase fraction (SPF) from 0.1-31.6%. Diploidy was seen in n = 90 (81.8%), low-hyperdiploidy in n = 10 (9.1%), high-hyperdiploidy in n = 7 (6.4%) with one case each (0.9% each) having near-tetraploidy, high-hypodiploidy and low-hypodiploidy. The DI of all viable cell populations in normal samples ranged from 0.96-1.05. Conventional karyotyping was performed in n=76/110 cases (70%) with n= 11/76 (15%) culture failures. The modal chromosome number ranged from 45 to 63. A concordance of 95.4% (n=62/65) was noted with corresponding FCM DI.
&#xD;

Conclusion: FCV-based ploidy is a sensitive technique that provides complementary information and ascertains a strong correlation with conventional cytogenetics across all haemato-lymphoid neoplasms. It can detect aneuploidy in all B-ALL and myeloma cases, even in hemodiluted samples with cytogenetic culture failure; supplement the diagnoses of erythroleukemia, and provide a useful screen for a higher grade lymph node disease in lymphoma cases with SPF &gt; 3%.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1340</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1340/904</pdf_url>
  </Article>
</Articles>
